Optimi Health Opens Access to $100 Million for Psychedelic Drug Expansion

Optimi Health Corp. has established an equity line of credit worth up to US$100 million, giving the Canadian psychedelic drug manufacturer significant potential access to capital as it expands its regulated psilocybin and MDMA business.

The agreement with Seven Knots, LLC could help Optimi increase manufacturing, pursue new markets and supply more approved treatment programs. It is also another sign that parts of the psychedelic industry are moving beyond research, retreats and speculative startups toward pharmaceutical production, international distribution and clinical infrastructure.

However, the headline requires an important qualification: Optimi did not receive a $100 million check.

The agreement gives the company the right—but not the obligation—to sell shares to Seven Knots over time. That provides flexibility, but every share sold may also dilute the ownership percentage of existing shareholders.

So, is this a major vote of confidence in psychedelic medicine? Potentially. Is the entire $100 million guaranteed to reach Optimi’s bank account? No.

Here is what the agreement actually says and why it matters.

What Is Optimi Health?

Optimi Health is a Canadian commercial-stage pharmaceutical manufacturer focused on regulated psychedelic drug products.

The company operates a Health Canada-licensed, GMP-compliant manufacturing facility in British Columbia. According to Optimi Health, it manufactures finished-dose natural psilocybin and MDMA capsules for authorized therapeutic and research programs.

Its product portfolio includes natural psilocybin extract, low-dose psilocybin capsules and multiple MDMA capsule strengths. These are pharmaceutical products intended for controlled and legally authorized settings—not consumer mushroom products sold through ordinary retail channels.

Optimi has also supplied products to authorized psychiatrists in Australia, where certain approved practitioners may use psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder under the country’s regulated Authorized Prescriber pathway.

That commercial foundation distinguishes Optimi from psychedelic companies that possess promising intellectual property but lack their own licensed manufacturing capabilities.

How the $100 Million Equity Line Works

On August 13, 2026, Optimi entered into a common-share purchase agreement with Seven Knots. The following day, the company disclosed the arrangement publicly and filed the relevant documents with the U.S. Securities and Exchange Commission.

The equity line allows Optimi to sell Seven Knots as much as US$100 million in common shares during the term of the facility.

Optimi controls whether and when it initiates a sale, subject to the agreement’s requirements. Seven Knots is then obligated to purchase the shares identified in the company’s notice.

Each individual draw is limited to US$2 million.

The purchase price will equal 97% of the lower of:

• The lowest sale price of Optimi’s common shares on the applicable purchase date; or
• The volume-weighted average price during the applicable purchase period.

In simpler language, Seven Knots receives approximately a 3% discount under the pricing formula. Optimi receives flexible access to capital without being required to sell the entire authorized amount at once.

A purchase period will end if Optimi’s share price drops below 85% of the previous trading day’s closing price—or below a higher minimum price established by Optimi.

The complete terms are contained in the company’s SEC filing and supporting documents.

Why This Is Not the Same as Receiving $100 Million

Calling this a “$100 million financing” can create the impression that the money has already been transferred. That is not what happened.

This is better understood as a financing pipeline.

Optimi may periodically sell shares when it needs capital and when market conditions make a transaction practical. The actual amount raised will depend on several variables, including:

• Optimi’s decision to initiate individual draws;
• Its share price and trading volume;
• The agreement’s pricing and ownership restrictions;
• Regulatory approvals;
• Investor demand and market conditions; and
• The number of shares Optimi is willing or permitted to issue.

The $100 million figure represents the facility’s maximum potential capacity—not guaranteed proceeds.

Optimi also cannot begin selling shares through the equity line until an associated Form F-1 registration statement is declared effective by the SEC. The agreement remains subject to applicable Canadian Securities Exchange policies as well.

The Convertible Notes Included in the Agreement

In exchange for Seven Knots making the facility available, Optimi issued the investor an unsecured, non-interest-bearing convertible promissory note with a principal amount of US$1.5 million.

If Optimi raises at least US$7 million through the equity line, it has agreed to issue an additional US$500,000 note under similar terms.

The notes mature 24 months after their respective issuance dates. Seven Knots may convert them into Optimi shares at 95% of the company’s 20-day volume-weighted average price, subject to a minimum conversion price of US$3 per share.

Optimi may also prepay the notes at their principal value using cash or, subject to certain conditions, shares.

The initial $1.5 million note is a real cost associated with establishing the facility—even if Optimi ultimately draws little or no money from the equity line. That detail deserves attention alongside the much larger $100 million headline.

Joseph Gunnar & Co., the exclusive placement agent for the agreement, is also entitled to a fee equal to 3% of gross proceeds raised through purchases under the facility.

What Could Optimi Do With the Capital?

Optimi has not promised that every dollar drawn will be assigned to one specific project. Nevertheless, the financing could support several parts of its psychedelic pharmaceutical operation.

Potential uses include:

Increasing pharmaceutical production

Commercial psychedelic treatment requires consistent products manufactured under strict quality and documentation standards. Scaling that system involves more than growing mushrooms or acquiring raw ingredients.

Manufacturers must test potency, monitor contaminants, validate production processes, maintain records and produce standardized doses that clinicians and regulators can trust.

Additional capital could help Optimi increase production capacity as regulated demand develops.

Expanding into additional markets

Psychedelic laws are evolving at dramatically different speeds across different countries.

Australia has already created a tightly controlled pathway for authorized psychiatrists to prescribe MDMA and psilocybin in limited circumstances. Other nations are expanding clinical trials, special-access programs or compassionate-use pathways.

Entering each jurisdiction can require regulatory filings, import permits, distribution relationships and product-specific approvals. Access to capital gives Optimi more flexibility to pursue those markets.

Supplying clinical trials

Drug developers and academic researchers need reliable supplies of GMP-grade psychedelic compounds. A company capable of manufacturing both active pharmaceutical ingredients and finished-dose products may be positioned to serve multiple research sponsors.

This “picks and shovels” approach could allow Optimi to participate in psychedelic drug development without relying entirely on the success of one proprietary therapy.

Building distribution and clinical partnerships

Manufacturing a drug is only part of the commercial process. Optimi must also connect its products with researchers, licensed prescribers, hospitals and regulated treatment networks.

Capital could support sales, distribution, regulatory compliance and international logistics as legal psychedelic treatment programs expand.

Why Investors Should Still Consider Dilution

The equity line gives Optimi financial flexibility, but that flexibility comes from selling common shares.

If the company issues a large number of new shares, existing investors will own a smaller percentage of the business unless they acquire additional stock. This is known as dilution.

The extent of that dilution will depend on how much capital Optimi raises and the price of its shares when each draw occurs. If the company’s stock trades at lower prices, Optimi must generally issue more shares to raise the same amount of money.

The agreement contains ownership restrictions preventing Seven Knots and its affiliates from owning more than 4.99% of Optimi’s outstanding shares through equity-line purchases. Conversions of the commitment notes have a separate 2.99% beneficial-ownership limitation.

Those restrictions limit how much Seven Knots may own at one time, but they do not eliminate the possibility of broader shareholder dilution.

Why This Matters for the Psychedelic Medicine Industry

The psychedelic sector has spent years confronting a fundamental question: Who will manufacture regulated drugs if psychedelic-assisted therapy reaches more patients?

Clinical enthusiasm alone does not create a functioning medical system. Legal treatment programs require:

• Pharmaceutical-grade active ingredients;
• Standardized finished doses;
• Qualified prescribers;
• Controlled storage and distribution;
• Quality-assurance testing;
• Regulatory documentation; and
• Reliable manufacturing capacity.

Optimi’s financing announcement centers on that less glamorous—but absolutely necessary—side of psychedelic medicine.

The next phase of the industry may not be defined exclusively by companies discovering new molecules. It may also be shaped by manufacturers capable of consistently producing familiar compounds such as psilocybin and MDMA to pharmaceutical standards.

A Sign of Progress, Not a Guarantee of Success

Optimi’s US$100 million equity facility could provide the company with substantial resources, particularly when combined with the US$15 million public offering it completed during its May 2026 Nasdaq listing. According to the company’s public-offering announcement, those earlier proceeds were intended to support production, distribution, market expansion and general working capital.

Still, access to money does not guarantee commercial success.

The regulated psychedelic market remains young. Treatment models can be expensive, approval pathways remain uncertain, and manufacturers depend on clinics, researchers and health systems building sustainable demand.

The equity line gives Optimi another financial tool. Whether that tool creates long-term value will depend on how much the company draws, the price at which it issues shares and whether its manufacturing expansion generates corresponding revenue.

The Bigger Picture

Psychedelic medicine is gradually developing the infrastructure expected of a serious pharmaceutical sector.

Research remains essential, but research cannot reach patients without manufacturing, quality control, regulatory compliance and distribution. Optimi Health is positioning itself within that infrastructure by producing standardized psilocybin and MDMA products for authorized clinical markets.

The $100 million equity line does not mean psychedelic legalization is suddenly inevitable. It does not mean Optimi possesses $100 million in new cash, and it certainly does not eliminate the risks facing the company or the industry.

It does mean a publicly traded psychedelic pharmaceutical manufacturer now has potential access to a much larger pool of growth capital.

That is a meaningful development—and one worth examining beyond the headline.

Frequently Asked Questions

Did Optimi Health receive $100 million?

No. Optimi established an equity line allowing it to sell as much as US$100 million in shares over time. The total amount ultimately raised could be substantially lower.

Who is providing the equity facility?

The common-share purchase agreement is with Seven Knots, LLC.

Does Optimi have to use the entire facility?

No. Optimi has the right, but not the obligation, to initiate share sales under the agreement.

What psychedelic drugs does Optimi manufacture?

Optimi manufactures pharmaceutical-grade natural psilocybin and MDMA products for authorized therapeutic and research programs.

Can Optimi immediately begin selling shares through the equity line?

No. The SEC must first declare the associated registration statement effective, and the facility remains subject to other applicable conditions.

Could the agreement dilute existing shareholders?

Yes. Raising money through newly issued common shares can reduce existing shareholders’ proportional ownership.

---

Financial and medical disclaimer: This article is for news, educational and informational purposes only. It is not investment advice, medical advice or a recommendation to purchase securities or use psychedelic substances. Psilocybin and MDMA remain controlled substances in the United States outside specifically authorized research and regulatory pathways.